BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 20647339)

  • 1. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer.
    Bisht S; Mizuma M; Feldmann G; Ottenhof NA; Hong SM; Pramanik D; Chenna V; Karikari C; Sharma R; Goggins MG; Rudek MA; Ravi R; Maitra A; Maitra A
    Mol Cancer Ther; 2010 Aug; 9(8):2255-64. PubMed ID: 20647339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
    Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
    Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: Implications for breast cancer chemoprevention in at-risk populations.
    Chun YS; Bisht S; Chenna V; Pramanik D; Yoshida T; Hong SM; de Wilde RF; Zhang Z; Huso DL; Zhao M; Rudek MA; Stearns V; Maitra A; Sukumar S
    Carcinogenesis; 2012 Nov; 33(11):2242-9. PubMed ID: 22831956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
    Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
    J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.
    Ali S; Ahmad A; Banerjee S; Padhye S; Dominiak K; Schaffert JM; Wang Z; Philip PA; Sarkar FH
    Cancer Res; 2010 May; 70(9):3606-17. PubMed ID: 20388782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment.
    Yallapu MM; Ebeling MC; Khan S; Sundram V; Chauhan N; Gupta BK; Puumala SE; Jaggi M; Chauhan SC
    Mol Cancer Ther; 2013 Aug; 12(8):1471-80. PubMed ID: 23704793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin enhances anti‑cancer efficacy of either gemcitabine or docetaxel on pancreatic cancer cells.
    Liu P; Ying Q; Liu H; Yu SQ; Bu LP; Shao L; Li XY
    Oncol Rep; 2020 Oct; 44(4):1393-1402. PubMed ID: 32945513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.
    Bisht S; Schlesinger M; Rupp A; Schubert R; Nolting J; Wenzel J; Holdenrieder S; Brossart P; Bendas G; Feldmann G
    J Nanobiotechnology; 2016 Jul; 14(1):57. PubMed ID: 27401816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model.
    Kunnumakkara AB; Diagaradjane P; Anand P; Harikumar KB; Deorukhkar A; Gelovani J; Guha S; Krishnan S; Aggarwal BB
    Int J Cancer; 2009 Nov; 125(9):2187-97. PubMed ID: 19623659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
    Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
    Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.
    Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Yadav VR; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
    Cancer Res; 2010 Nov; 70(21):8695-705. PubMed ID: 20864511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.
    Wang ZH; Chen H; Guo HC; Tong HF; Liu JX; Wei WT; Tan W; Ni ZL; Liu HB; Lin SZ
    Int J Oncol; 2011 Nov; 39(5):1123-31. PubMed ID: 21743963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
    Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
    J Cell Biochem; 2010 May; 110(1):171-81. PubMed ID: 20213764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.
    Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
    Int J Cancer; 2012 Aug; 131(3):E292-303. PubMed ID: 21935918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.
    Tran Cao HS; Bouvet M; Kaushal S; Keleman A; Romney E; Kim G; Fruehauf J; Imagawa DK; Hoffman RM; Katz MH
    Mol Cancer Ther; 2010 Jul; 9(7):2068-78. PubMed ID: 20606044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperlongumine Suppresses Growth and Sensitizes Pancreatic Tumors to Gemcitabine in a Xenograft Mouse Model by Modulating the NF-kappa B Pathway.
    Wang Y; Wu X; Zhou Y; Jiang H; Pan S; Sun B
    Cancer Prev Res (Phila); 2016 Mar; 9(3):234-44. PubMed ID: 26667450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study.
    Brandi G; Tavolari S; Guarnieri T; Di Marco M; Paterini P; Macchini M; Di Girolamo S; Papi A; De Rosa F; Biasco G
    Pancreas; 2014 Jan; 43(1):53-63. PubMed ID: 24201777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
    Hu B; Sun D; Sun C; Sun YF; Sun HX; Zhu QF; Yang XR; Gao YB; Tang WG; Fan J; Maitra A; Anders RA; Xu Y
    Biochem Biophys Res Commun; 2015 Dec; 468(4):525-32. PubMed ID: 26482853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers.
    Tharakan ST; Inamoto T; Sung B; Aggarwal BB; Kamat AM
    Biochem Pharmacol; 2010 Jan; 79(2):218-28. PubMed ID: 19682434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer.
    Husain K; Francois RA; Yamauchi T; Perez M; Sebti SM; Malafa MP
    Mol Cancer Ther; 2011 Dec; 10(12):2363-72. PubMed ID: 21971120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.